Clinical Report: Advances in Hodgkin Lymphoma Treatment
Overview
The SWOG S1826 trial indicates a 1-year progression-free survival of 94% for Nivolumab-AVD compared to 86% for BV-AVD.
Background
Classical Hodgkin lymphoma (cHL) is a rare malignancy characterized by Reed–Sternberg cells. Advanced stages present treatment challenges, and immune checkpoint inhibitors like nivolumab are being studied as potential options.
Data Highlights
| Study | Findings |
|---|---|
| SWOG S1826 | 1-year PFS: 94% (Nivo-AVD) vs. 86% (BV-AVD) |
| CheckMate 205 | Severe adverse events: infections (44%), fatigue (39%), cough (36%), diarrhea (33%) |
| CheckMate 039 | Neutropenia: 37% of patients |
Key Findings
- Nivolumab-AVD shows a 1-year progression-free survival of 94% compared to 86% for BV-AVD.
- Neutropenia occurred in 56% of patients receiving Nivo-AVD, with 48% experiencing grade ≥ 3 neutropenia.
- Infection-related complications were similar between Nivo-AVD and BV-AVD.
- Prophylactic G-CSF was required for BV-AVD but not for Nivo-AVD.
Clinical Implications
Clinicians should consider the safety profile of Nivolumab-AVD based on the findings from the SWOG S1826 trial.
Conclusion
The SWOG S1826 trial demonstrates improved progression-free survival for Nivolumab-AVD compared to BV-AVD.
Related Resources & Content
- Brice et al., 2021 -- Advances in Hodgkin Lymphoma Treatment
- Herrera et al., 2024 -- SWOG S1826 Trial Results
- Lai et al., 2019 -- Nivolumab and AVD Combination Study
- FDA, 2026 -- FDA Approval of Nivolumab for Hodgkin Lymphoma
- the asco post — Nivolumab Plus AVD as Front-Line Therapy in Older Adults With Classical Hodgkin Lymphoma
- The ASCO Post — New Data From SWOG S1826 Trial May Confirm Benefit of Nivolumab Plus AVD in Patients With Hodgkin Lymphoma
- the asco post — Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma
- The ASCO Post — Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
- Nivolumab Plus AVD as Front-Line Therapy in Older Adults
- New Data From SWOG S1826 Trial
- Nivolumab Plus AVD Reduces Disease Progression Risk
- FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma | FDA
- S1826 Data Confirm Nivo-AVD Benefit in Hodgkin Lymphoma | SWOG
- Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
